Belgium
AbolerIS Pharma, headquartered in Belgium, is at the forefront of developing innovative therapeutic approaches aimed at regulating the immune system, with a particular focus on inducing immune tolerance. Founded in 2019 by a team with deep expertise in regulatory T cells and tolerance mechanisms, the company is positioned to address unmet needs in managing inflammatory, autoimmune, and degenerative diseases.
The startup’s unique approach seeks to balance immune response modulation—preserving beneficial responses while curbing detrimental ones. This could be pivotal in transforming treatment landscapes across several indication areas.
A recent €27.30M Series A investment was secured in September 2023, backed by a consortium of investors including Newton BioCapital, Sambrinvest, Turenne Capital, and SFPIM. This funding positions AbolerIS Pharma to further its cutting-edge advancements and scale its therapeutic developments. Their support highlights a strong confidence in the startup’s potential to revolutionize immune-based therapies.
